Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 12/20 | 0.47 |
| ▸ | MMP8 | P22894 | 7/20 | 0.47 |
| ▸ | MMP9 | P14780 | 5/20 | 0.47 |
| ▸ | MMP3 | P08254 | 10/20 | 0.41 |
| ▸ | MMP1 | P03956 | 9/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 6/20 | 0.41 |
| ▸ | FCER2 | P06734 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6895453 | 1.00 | MMP2 (0.47) | MMP2MMP8MMP9MMP3MMP1 | |
| SCHEMBL6895064 | 0.93 | L3MBTL1 (0.43) | MMP2MMP8MMP9MMP3MMP1 | |
| SCHEMBL6895067 | 0.93 | L3MBTL1 (0.43) | MMP2MMP8MMP9MMP3MMP1 | |
| SCHEMBL6899397 | 0.89 | L3MBTL1 (0.40) | MMP2MMP8MMP9L3MBTL1REN | |
| SCHEMBL6899389 | 0.89 | L3MBTL1 (0.40) | MMP2MMP8MMP9L3MBTL1REN | |
| SCHEMBL6898184 | 0.84 | L3MBTL1 (0.41) | MMP2MMP8MMP9MMP3MMP1 | |
| SCHEMBL6898179 | 0.84 | L3MBTL1 (0.41) | MMP2MMP8MMP9MMP3MMP1 | |
| SCHEMBL6891301 | 0.82 | L3MBTL1 (0.50) | MMP8MMP9L3MBTL1REN | |
| SCHEMBL6897813 | 0.81 | L3MBTL1 (0.46) | MMP8MMP9L3MBTL1FCER2REN | |
| SCHEMBL6895033 | 0.81 | MME (0.46) | MMP2MMP8MMP9L3MBTL1REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | MMP2 3359/4885MMP8 3131/4885MMP9 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.